These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 37714724)

  • 1. LDR-Brachytherapy monotherapy appears unsuited for NCCN unfavorable intermediate-risk prostate cancer patients.
    Boehle A; Zywietz D; Robrahn-Nitschke I; Lusch A; König IR
    Urol Oncol; 2023 Nov; 41(11):454.e17-454.e24. PubMed ID: 37714724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brachytherapy monotherapy may be sufficient for a subset of patients with unfavorable intermediate risk prostate cancer.
    King MT; Chen MH; Moran BJ; Braccioforte MH; Buzurovic I; Muralidhar V; Yang DD; Mouw KW; Devlin PM; D'Amico AV; Nguyen PL; Orio PF
    Urol Oncol; 2018 Apr; 36(4):157.e15-157.e20. PubMed ID: 29276060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of 15 Gy HDR-BT boost plus EBRT in intermediate-risk prostate cancer: Analysis of over 500 patients.
    Martell K; Mendez LC; Chung HT; Tseng CL; Alayed Y; Cheung P; Liu S; Vesprini D; Chu W; Wronski M; Szumacher E; Ravi A; Loblaw A; Morton G
    Radiother Oncol; 2019 Dec; 141():149-155. PubMed ID: 31522882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined-modality
    Boehle A; Katic K; König IR; Robrahn-Nitschke I; Renner P; Brandenburg B
    World J Urol; 2019 Nov; 37(11):2355-2363. PubMed ID: 30707304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detectable end of radiation prostate specific antigen assists in identifying men with unfavorable intermediate-risk prostate cancer at high risk of distant recurrence and cancer-specific mortality.
    Hayman J; Phillips R; Chen D; Perin J; Narang AK; Trieu J; Radwan N; Greco S; Deville C; McNutt T; Song DY; DeWeese TL; Tran PT
    Prostate; 2018 Jun; 78(8):623-630. PubMed ID: 29520847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes and prognostic factors in intermediate-risk prostate cancer: multi-institutional analysis of the Spanish RECAP database.
    Hervás A; Pastor J; González C; Jové J; Gómez A; Casaña M; Villafranca E; Mengual JL; Muñoz V; Henriquez I; Muñoz J; Collado E; Clemente J
    Clin Transl Oncol; 2019 Jul; 21(7):900-909. PubMed ID: 30536208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing the impact of brachytherapy boost and androgen deprivation therapy on survival outcomes for patients with unfavorable intermediate-risk prostate cancer patients treated with external beam radiotherapy.
    Andruska N; Agabalogun T; Fischer-Valuck BW; Brenneman RJ; Huang Y; Gay HA; Michalski JM; Carmona R; Baumann BC
    Brachytherapy; 2022; 21(5):617-625. PubMed ID: 35641370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brachytherapy improves biochemical failure-free survival in low- and intermediate-risk prostate cancer compared with conventionally fractionated external beam radiation therapy: a propensity score matched analysis.
    Smith GD; Pickles T; Crook J; Martin AG; Vigneault E; Cury FL; Morris J; Catton C; Lukka H; Warner A; Yang Y; Rodrigues G
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):505-16. PubMed ID: 25596107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the role of external beam radiation therapy in combination with brachytherapy versus brachytherapy alone for unfavorable intermediate-risk prostate cancer.
    Andruska N; Michalski JM; Carmona R; Agabalogun T; Brenneman RJ; Gay HA; Fischer-Valuck BW; Baumann BC
    Brachytherapy; 2022; 21(3):317-324. PubMed ID: 35123889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term and pathological outcomes of low- and intermediate-risk prostate cancer after radical prostatectomy: implications for active surveillance.
    Meissner VH; Woll M; Ankerst DP; Schiele S; Gschwend JE; Herkommer K
    World J Urol; 2021 Oct; 39(10):3763-3770. PubMed ID: 33973043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different outcomes among favourable and unfavourable intermediate-risk prostate cancer patients treated with hypofractionated radiotherapy and androgen deprivation therapy.
    Bracci S; Osti MF; Agolli L; Bertaccini L; De Sanctis V; Valeriani M
    Radiat Oncol; 2016 Jun; 11():78. PubMed ID: 27276878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term oncologic outcomes of low dose-rate brachytherapy compared to hypofractionated external beam radiotherapy for intermediate -risk prostate cancer.
    Sanmamed N; Joseph L; Crook J; Craig T; Warde P; Tomasso AD; Chung P; Berlin A; Bayley A; Saibishkumar EP; Glicksman R; Raman S; Catton C; Helou J
    Brachytherapy; 2023; 22(2):188-194. PubMed ID: 36549968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. After ASCENDE-RT: Biochemical and survival outcomes following combined external beam radiotherapy and low-dose-rate brachytherapy for high-risk and unfavourable intermediate-risk prostate cancer, a population-based analysis.
    Oh J; Morris WJ; Spadinger I; Tyldesley S; Keyes M; Halperin R; Crook J; Lapointe V; Pickles T
    Brachytherapy; 2022; 21(5):605-616. PubMed ID: 35729030
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Smile TD; Tom MC; Halima A; Ciezki JP; Reddy CA; Stephans KL; Mian OY; Zhang RX; Klein EA; Campbell S; Ulchaker J; Angermeier K K; Tendulkar RD
    Brachytherapy; 2022; 21(1):85-93. PubMed ID: 34656435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low dose rate brachytherapy (LDR-BT) as monotherapy for early stage prostate cancer in Italy: practice and outcome analysis in a series of 2237 patients from 11 institutions.
    Fellin G; Mirri MA; Santoro L; Jereczek-Fossa BA; Divan C; Mussari S; Ziglio F; La Face B; Barbera F; Buglione M; Bandera L; Ghedi B; Di Muzio NG; Losa A; Mangili P; Nava L; Chiarlone R; Ciscognetti N; Gastaldi E; Cattani F; Spoto R; Vavassori A; Giglioli FR; Guarneri A; Cerboneschi V; Mignogna M; Paoluzzi M; Ravaglia V; Chiumento C; Clemente S; Fusco V; Santini R; Stefanacci M; Mangiacotti FP; Martini M; Palloni T; Schinaia G; Lazzari G; Silvano G; Magrini S; Ricardi U; Santoni R; Orecchia R
    Br J Radiol; 2016 Sep; 89(1065):20150981. PubMed ID: 27384381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of intermediate-risk prostate cancer with Cs-131: Long-term results from a single institution.
    Rodríguez-López JL; Patel AK; Benoit RM; Beriwal S; Smith RP
    Brachytherapy; 2022; 21(1):79-84. PubMed ID: 34756821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative analysis between low-dose-rate brachytherapy and external beam radiation therapy for low- and intermediate-risk prostate cancer in Asian men.
    Li Y; Chan Kong Ngai T; Zhou S; Yap Haw Hwong J; Pang Pei Ping E; Ong Li Kuan A; Wang Lian Chek M; Chua Lee Kiang M; Looi WS; Nei WL; Chua ET; On WLK; Tan Wee Kiat T; Yuen Shyi Peng J; Tuan Kit Loong J
    Acta Oncol; 2021 Oct; 60(10):1291-1295. PubMed ID: 34259123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Excessive waitlists and delays to treatment with low-dose-rate brachytherapy predict an increased risk of recurrence and metastases in intermediate-risk prostatic carcinoma.
    Khanolkar RA; Quon H; Thind K; Sia M; Roumeliotis M; Husain S; McGeachy P; Meyer T; Martell K
    Clin Transl Radiat Oncol; 2021 Sep; 30():38-42. PubMed ID: 34307912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does ADT benefit unfavourable intermediate risk prostate cancer patients treated with brachytherapy boost and external beam radiotherapy? A propensity-score matched analysis.
    Mendez LC; Martell K; Warner A; Tseng CL; Chung H; Loblaw A; Rodrigues GB; Morton G
    Radiother Oncol; 2020 Sep; 150():195-200. PubMed ID: 32619455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of the NCCN prostate cancer favorable- and unfavorable-intermediate risk groups among men treated with I-125 low dose rate brachytherapy monotherapy.
    Tom MC; Reddy CA; Smile TD; Zhang RX; Ciezki JP; Stephans KL; Mian OY; Klein EA; Campbell S; Ulchaker J; Angermeier K; Tendulkar RD
    Brachytherapy; 2020; 19(1):43-50. PubMed ID: 31813740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.